Analysis-Nike’s struggles test investor confidence in CEO Hill’s turnaround effort Investing.com · News 13m ago
Liquidia stock price target cut to $58 by H.C. Wainwright on patent uncertainty Investing.com · News 13m ago
H.C. Wainwright reiterates Nektar Therapeutics stock rating on alopecia data Investing.com · News 13m ago
Foghorn Therapeutics stock price target cut to $5 by H.C. Wainwright on program halt Investing.com · News 13m ago
Guggenheim raises MBX Biosciences price target to $150 on obesity drug potential Investing.com · News 19m ago